FDA issues slew of warning letters for GMP and unapproved drug violations
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionComplianceEnforcementGMPManufacturingOTCPharmaceuticalsQuality Assurance and ControlRecallsRegulatory Intelligence/PolicySterile drugsUnited StatesWarning letters